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Summary This review forms part of a series of annual updates that summarize the evidence base
for atopic eczema (AE), providing a succinct guide for clinicians and patients. It provides
a summary of key findings from 26 systematic reviews that were published during
2015, and focuses on the treatment and prevention of AE. For systematic reviews on the
epidemiology and methodological issues, see Part 1 of this update. Topical corticosteroid
withdrawal syndrome, ‘steroid addiction’, has been evaluated in a high-quality system-
atic review, which helps better define this entity and the risk factors for it. A Cochrane
Review has not demonstrated any association between topical corticosteroid use in preg-
nancy and adverse outcomes, although very large quantities of potent/very potent topi-
cal corticosteroids may be associated with reduced birth weight. House dust mite
avoidance strategies do not appear to prevent AE. Exposure to probiotics prenatally and
in early infancy may help prevent AE, but there is no evidence that maternal diet or sup-
plementation has a preventative effect.
Background
Atopic eczema (AE) is one of the most prevalent diseases
worldwide,1 and its study is a fast-moving field. The aim
of this evidence update is to highlight the clinical and
research implications from systematic reviews (SRs)
published during 2015, summarizing the findings of
these SRs on the treatment and prevention of AE. For
an update of SRs on the methodological issues and epi-
demiology of AE, see Part 1 of this update. Similar evi-
dence updates on AE have been published previously,
along with the details of the search methods used.2–4
Treatment of atopic eczema
Emollients
Emollients are a mainstay of AE treatment, but are
poorly investigated. The review by Lindh and Bradley5
of moisturizer efficacy evaluated 32 AE studies, includ-
ing 25 randomized controlled trials (RCTs), with a total
of 2332 participants. Most studies reported beneficial
effects on clinical symptoms, transepidermal water loss
(TEWL) and stratum corneum (SC) hydration, with the
clinical effect appearing greatest for products containing
urea. Studies were mostly of short duration (ranging
from 90 min to 6 months), involved few patients (range
10–173) and carried a high risk of bias. Meta-analysis
was precluded owing to significant heterogeneity in the
control intervention and the measured outcomes.
Topical corticosteroids: side effects and safety
Three SRs assessed various safety considerations sur-
rounding topical corticosteroid (TCS) use.
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TCS use and skin atrophy was evaluated in a
review covering 15 AE studies (8 RCTs, 7 open-label
observational studies).6 The authors reported that the
benefit/risk ratio depended on TCS potency. Study
duration ranged from 2 to 52 weeks, but no specific
data were included on the duration of any local
effects post-TCS cessation. Whether subclinical atro-
phy translates to clinically meaningful changes is still
unclear.
Hajar et al.7 conducted an SR assessing TCS with-
drawal syndrome (‘steroid addiction’) an adverse effect
arising from TCS withdrawal after prolonged or inap-
propriate use of moderate- to high-potency TCS,
mainly on the face and, to a lesser extent, the genitals.
The review assessed 34 studies (19 case series, 13 case
reports, 2 cross-sectional studies), involving 251
patients with AE, most of whom were female. Ery-
thema was noted in 92% of patients, with papulon-
odular or pustular lesions present in approximately
50%. No effective management strategy was estab-
lished, although TCS discontinuation was recom-
mended.
An updated Cochrane Review8 evaluated the effect of
TCS use on pregnancy outcomes, with a total of
1 601 515 patients. Most studies found no causal asso-
ciations between maternal exposure to TCS and adverse
pregnancy outcomes. However, a probable association
between low birth weight and sustained maternal use
of potent to very potent TCS was reported. The overall
quality of the evidence was low.
Topical calcineurin inhibitors
A Cochrane Review9 assessed the efficacy and safety of
topical tacrolimus for moderate to severe AE, with a
total of 5885 patients in 20 RCTs, which were mostly
short-term (range 13 days to 6 months). Tacrolimus
(0.03%; 0.1%) was more effective than mild-potency
TCS and pimecrolimus, but results were equivocal
compared with moderate to potent TCS. Transient
itching and burning were more commonly observed
with tacrolimus than with TCS, but there was no dif-
ference in the rate of skin infections. There was no evi-
dence to support an increased risk of malignancy with
the use of tacrolimus. Variation in drug dose, out-
comes and follow-up periods precluded meta-analysis.
A separate review of SRs assessing topical calcineurin
inhibitors in AE10 concluded that tacrolimus is an
effective and cost-effective alternative treatment to
TCS. No formal quality assessment of the included
studies was performed.
Phototherapy
Perez-Ferriols11 and colleagues evaluated the efficacy of
photo(chemo)therapy for moderate to severe AE. Evi-
dence from 21 studies with a total of 961 patients sup-
ported narrowband ultraviolet B (NB-UVB) and UVA1
phototherapy use, but data on long-term effects, particu-
larly in childhood, were limited. Few data were available
regarding the efficacy of psoralen (P)UVA, and further
studies using conventional treatment schedules are
needed to establish the relative efficacy of NB-UVB and
UVA1. An SR by Dogra et al.12 drew similar conclusions.
Psychological and educational interventions and
approaches to improving atopic eczema treatment
There have been three SRs of psychological and edu-
cational interventions for AE published in the period of
this update. Eccleson and colleagues13 updated their
Cochrane Review on psychological therapies for par-
ents of young people with chronic illness. Only one
study related to AE was included, and this compared
parental education using behavioural-based group
education or video education with standard care. The
authors suggested that parental education, particularly
video education, improved AE symptoms overall, but
there was a high risk of both attrition and reporting
bias, making it difficult to draw firm conclusions.
A health technology assessment14 of educational inter-
ventions to improve health-related quality of life (QoL)
included two RCTs involving children/adolescents with
AE and their carers (1141 participants) and an RCT of
50 adult patients with either AE or psoriasis. Despite
some evidence hinting at possible benefit, there is
uncertainty as to whether educational interventions
are clinically effective or cost-effective, and which types
of interventions are most likely to be beneficial in differ-
ent countries. Lee et al.15 qualitatively assessed 15
studies of educational programmes for children with
AE, and proposed four key themes to be included in AE
support interventions: (i) tailored support by age or AE
severity, with a patient- and family-centred approach;
(i) well-trained educators (evidence particularly favour-
ing nurse-led programmes and topical demonstrations);
(iii) use of diverse educational methods including web-
based education; and (iv) focus on emotional support
and improving QoL of children and their families.
A review of nine studies (including four RCTs)16
investigated multidisciplinary approaches for patients
(encompassing educational, psychological, behavioural
and nutritional interventions), and found that most
studies demonstrated improvements in AE severity.
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There were considerable limitations, including variabil-
ity in study design and outcomes.
Bass et al.17 evaluated different methods to increase
adherence to AE treatment (indirectly inferred from
changes in AE severity or quality of life in many
cases). Assessing the 7 included studies (760 partici-
pants), the authors concluded that written eczema
action plans, extra clinic visits and educational work-
shop attendance may improve treatment adherence.
They advised further research on how currently avail-
able treatments could be better utilized.
In summary, despite some suggestion of benefit, it is
not clear which types of psychological/educational
interventions work best, and how these may need to
be tailored depending on the resource limitations and
patient needs in different countries.
Acupuncture
Two SRs investigated acupuncture efficacy in AE. Tan
et al.,18 who strictly defined AE for inclusion in the
review, found no RCTs. By contrast, Ma and col-
leagues19 reported 5 RCTs (four by the same research
group), and 1 prospective observational study, which
had a total of 170 participants. Although itch mea-
surements were lower in the acupuncture groups, the
studies were small, and the acupuncture regimens and
control arms varied significantly.
Bathing
Sarre et al.20 evaluated the impact of water submersion
(5–15 min) on the skin of patients with AE from 4
heterogeneous studies (3 RCTs, 1 crossover) with 63 par-
ticipants in total. The review concluded that bathing had
no impact on various functional parameters, including
TEWL and SC hydration. However, the included studies
were small and heterogeneous, while important potential
confounders, such as concomitant use of emollients or
water temperature, were not addressed.
House dust mite avoidance for treatment of atopic
eczema
Nankervis et al.21 performed a Cochrane Review
assessing house dust mite reduction and avoidance
measures for the treatment of AE, which assessed 7
RCTs with a total of 324 participants. Modest treat-
ment responses with dust mite reduction techniques
were reported in one small, low-quality study of
patients with AE with aeroallergen sensitivities, but
the value and optimal timing of house dust mite
reduction for patients with AE in general is unknown.
Overall, the evidence was of very low quality.
Prevention of atopic eczema
Probiotics
Zuccoti et al.22 evaluated 17 heterogeneous RCTs with
a total of 4755 parents and children. Prenatal and
perinatal exposure to probiotics (in either the mother
or child after birth) decreased the risk of AE develop-
ment in children at high risk of atopy (risk ratio 0.78;
95% CI 0.69–0.89; P = 0.0003), with a number
needed to treat of 13. The preventative effect appeared
confined to the first 24 months of life. The observed
effects were most convincing when probiotic mixtures
(rather than single strains) were used. Two other SRs
gave similar findings, although one found probiotics
were associated with a reduced AE risk over a sus-
tained period (> 5 years).23,24 It is unclear which pro-
biotic strains are most effective, or when these are
best delivered during pregnancy and early life.
Maternal diet
A review by Beckhaus et al.25 of 24 studies (23
prospective, 1 retrospective) found insufficient evidence
to recommend any maternal diet or supplementation
to prevent childhood AE.25
A Cochrane Review26 of six RCTs found that pre-
natal n-3 long-chain polyunsaturated fatty acid
(LCPUFA) dietary supplementation did not reduce AE
incidence. A decrease in IgE-mediated AE between 1
and 3 years of age was reported in two trials including
high-risk patients. Studies included different regimens,
making direct comparisons difficult.
Another review by Best et al.27 evaluating prenatal n-
3 LCPUFA exposure for AE prevention in eight prospec-
tive cohort studies and four RCTs found inconsistent evi-
dence. A meta-analysis demonstrated a significant
reduction in AE incidence (defined as eczema symptoms
and a positive skin prick test) at 12 months (relative risk
0.53; 95% CI 0.35–0.81; P = 0.004), but this benefit
was lost by 3 years of age. There was significant varia-
tion in diet and regimen timings between studies, making
meaningful conclusions difficult to draw.
Breast feeding
Lodge et al.28 reviewed 42 observational studies (with
472 488 participants) and found low- to very low-
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quality evidence that breastfeeding reduces the risk of
eczema development up to 2 years of age. After this age,
the protective effect was lost. The studies failed to adjust
for important confounders, including a family history of
atopy, and there were often long recall periods.
House dust mite avoidance
A review by Bremmer et al.29 of 7 RCTs with 3040
patients indicated that dust mite avoidance strategies,
alone or in combination with other allergen avoidance
strategies, did not reduce the risk of developing AE. The
included studies mostly had a moderate risk of bias, and
the criteria used to diagnose AE were unclear. Combin-
ing three trials using a dust mite avoidance approach in
a meta-analysis showed no benefit in the primary pre-
vention of AE (RR = 1.08; 95% CI 0.78–1.49).
Learning points
• Although emollients are a mainstay treatment
for AE, they have been poorly investigated to
date, and head-to-head comparisons are lacking.
• TCS withdrawal syndrome (‘steroid addiction’)
appears to be a distinct adverse effect of TCS use,
resulting from prolonged, inappropriate or fre-
quent use of moderate- to high-potency TCS, par-
ticularly on the face.
• The use of TCS during pregnancy does not
appear to be related to adverse pregnancy out-
comes, although the use of very large quantities
of potent to very potent TCS may be associated
with low birth weight.
• Evidence supports the use of narrowband UVB
and UVA1 phototherapy to treat AE, but data for
treating childhood AE with phototherapy are lim-
ited and there are few data on long-term effects.
• Very low-quality evidence indicates that house
dust mite reduction and avoidance measures may
be beneficial for patients with AE who have
aeroallergen sensitivities, but these approaches do
not appear to prevent the development of AE.
• Exposure to probiotics during pregnancy and in
early infancy may reduce the risk of developing
AE, although the duration of this protective effect
is unclear.
• There is no consistent evidence that maternal
diet helps to prevent AE, but there is some evi-
dence that n-3 long chain polyunsaturated fatty
acid dietary supplementation may reduce the
incidence of AE.
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CPD questions
Learning objective
To demonstrate up-to-date knowledge of prevention
and treatment in atopic eczema.
Question 1
Which of the following statements regarding topical
treatments for atopic eczema (AE) is true?
(a) There is evidence indicating a probable association
between the use of potent to very potent topical
corticosteroids in pregnancy and craniofacial con-
genital abnormalities.
(b) A Cochrane Review found evidence for an
increased risk of skin infections with tacrolimus
use compared with topical corticosteroids.
(c) Mild-potency topical corticosteroids were found to
be equivalent in efficacy to tacrolimus 0.1%.
(d) Evidence suggests that the beneficial clinical effects
of moisturizers may be highest for those contain-
ing urea.
(e) A Cochrane Review found evidence for an
increased risk of malignancy with tacrolimus use.
Question 2
Which of the following statements regarding topical
corticosteroid (TCS) ‘addiction’/withdrawal is correct?
(a) This is most commonly seen in male patients.
(b) It can be the consequence of a short period of a
very potent TCS on the face.
(c) The genitals are the most commonly affected site.
(d) Erythema is the most common sign.
(e) The topical corticosteroid should be continued.
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Question 3
Which of the following statements regarding the pre-
vention of AE is true?
(a) Maternal intake of n-3 long chain polyunsaturated
fatty acids may reduce the incidence of AE.
(b) Maternal intake of probiotics during pregnancy
does not appear to reduce the incidence of AE in
the first 24 months of life.
(c) Breastfeeding may reduce the long-term incidence
of AE.
(d) House dust mite avoidance strategies may reduce
the risk of developing AE.
(e) Maternal intake of vitamin D may reduce the inci-
dence of AE.
Question 4
Recent systematic reviews have found robust evidence
of effectiveness for which treatment for AE?
(a) Psoralen ultraviolet A (PUVA) phototherapy.
(b) Acupuncture.
(c) Emollients.
(d) Educational programmes.
(e) Topical tacrolimus.
Question 5
Which of the following statements about treatments
for AE is true?
(a) Short-term tap-water submersion of AE skin has
been shown to increase transepidermal water loss.
(b) Multidisciplinary approaches to management have
not been shown to affect AE severity.
(c) Evidence suggests that patients with AE should use
house dust mite reduction and avoidance measures.
(d) Written eczema action plans have been associated
with improved AE treatment adherence.
(e) A number of studies indicate that psychological
therapies are helpful for managing AE.
Instructions for answering questions
This learning activity is freely available online at
http://www.wileyhealthlearning.com/ced
Users are encouraged to
• Read the article in print or online, paying particular
attention to the learning points and any author con-
flict of interest disclosures
• Reflect on the article
• Register or login online at http://www.wileyhealth
learning.com/ced and answer the CPD questions
• Complete the required evaluation component of the
activity
Once the test is passed, you will receive a certificate
and the learning activity can be added to your RCP
CPD diary as a self-certified entry.
This activity will be available for CPD credit for
2 years following its publication date. At that time, it
will be reviewed and potentially updated and extended
for an additional period.
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